ArticleFrontiers in psychiatry2026
Recognizing supraventricular tachyarrhythmias in female patients: beyond palpitations to symptoms like anxiety, panic, and nausea.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Study objective: To investigate sex-specific differences in the clinical presentation of Supraventricular Tachycardia (SVT) in patients presenting to a tertiary care Emergency Department (ED) and to examine whether sex-related differences in management and follow-up are observed in our cohort. Methods: We conducted a retrospective cohort study of adults presenting with palpitations and diagnosed with SVT at a tertiary care ED in 2019. Diagnoses were confirmed by electrocardiogram review. The prima-ry outcome was sex-specific differences in symptom presentation. Secondary outcomes included differences in acute treatment, treatment success, follow-up recommendations and etiologic factors. Multivariable regression analyses adjusted for age, Charlson Comorbidity Index, and prior SVT treat-ment were performed. Results: Of 375 screened patients, 278 were included (45.3% women; mean age 49.5 years (SD 19) of all pa-tients). Women had a significantly higher prevalence of hypokalaemia (11.1% vs 3.3%; adjusted odds ratio [OR] 3.7 (95% CI 1.3-10.9, p=0.018)) and reported more overall symptoms (adjusted difference 0.3, 95% CI 0.03 - 0.56, p=0.027). Leading symptoms such as palpitations (OR 3.5 (95% CI 1.3-9.0, p=0.011)), nausea (OR 2.2 (95% CI 1.1-4.5, p=0.026)), and anxiety (OR 2.9 (95% CI 1.1-8.1, p=0.031)) were more frequent in women when presenting in the ED. Atrial fibrillation was the most common di-agnosis in both sexes without any significant sex-related difference in the frequency. Atrioventricular nodal reentry tachycardia was more frequent in women (12.7% vs. 5.9%, OR 2.4 (95% CI 1.01-5.8, p=0.047)), whereas atrial flutter was significantly less common in women (3.2% vs. 11.2%, OR 0.2 (95% CI 0.07-0.7, p=0.011)). No significant sex differences were observed in acute treatment, treat-ment success or follow-up. Conclusion: Women with SVT present with a higher symptom burden and a distinct symptom profile. Clinicians should maintain a high index of suspicion and ensure electrocardiographic evaluation in all patients with compatible symptoms regardless of sex, but particularly in women presenting with palpitations, nausea, or anxiety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.